crizanlizumab
crizanlizumab: sourced relationships with 1 company · 4 clinical trials tracked · 1 FDA decision.
crizanlizumab evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could crizanlizumab → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2019-11-15 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (4)
Managed Access Programs for SEG101, Crizanlizumab
A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises
Primary endpoint: Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Primary endpoint: Not Applicable as this protocol is to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab study
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Primary endpoint: Annualized Rate of Vaso-occlusive Crisis (VOC) Events Leading to a Healthcare Visit
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with crizanlizumab?
crizanlizumab has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve crizanlizumab?
BioSniper tracks 4 clinical trials involving crizanlizumab.
What is crizanlizumab's latest FDA decision?
The most recent tracked FDA decision for crizanlizumab is Approval, dated November 15, 2019.